ReviewClinical and molecular hepatology2025
Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment.
Review in Clinical and molecular hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Steatosis liver index: A validated machine learning model using clinical data distinguishes steatotic liver disease phenotypes.Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2026Article
- Associations of General and Central Obesity with Cardiovascular Risk by Menopausal and MASLD Status.Biomedicines · 2026Article
- Simplified definition and imaging-based stratification of at-risk MASH using magnetic resonance elastography.Hepatology communications · 2026Article
- Risk of HCC in Elderly Patients With MASLD: Proposal of an Effective Surveillance Strategy.Journal of gastroenterology and hepatology · 2026Article
- Artificial Intelligence, Real Results: AI Successfully Risk-Stratifies Patients with MASLD.Digestive diseases and sciences · 2026Article
- Predictors of Discordance Between Controlled Attenuation Parameter and Magnetic Resonance-Proton Density Fat Fraction in Hepatic Steatosis.Clinical and translational gastroenterology · 2026Article
- Metabolic Pathways Linking Atherosclerotic Cardiovascular Disease With Metabolic Dysfunction-Associated Steatotic Liver Disease.Current atherosclerosis reports · 2026Review
- Metabolic Dysfunction-Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach.The Kaohsiung journal of medical sciences · 2026Review
- p53: from understanding its structure to advances in therapeutic targeting.Signal transduction and targeted therapy · 2026Review
- The role and possible mechanism of intestinal fungi in the progression of chronic liver diseases.NPJ biofilms and microbiomes · 2026Review
- Kidney-alone transplantation in prior SLK candidates: a national registry analysis.Transplant international : official journal of the European Society for Organ Transplantation · 2026Article
- Convergent Metabolic Pathways in MASH Therapeutics: An AMPK-Centric Analysis.Journal of cellular and molecular medicine · 2026Review
- Nanotherapeutic Strategies for MASLD: From Pathological Mechanisms to Targeted Delivery Systems.International journal of nanomedicine · 2026Review
- From mechanisms to management: Early detection and improved treatment of MASLD and its related hepatocellular carcinoma.Hepatology communications · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease, formerly referred to as non-alcoholic fatty liver disease, is the most common liver disease in Western countries and has emerged as the leading indication for liver transplantation. Metabolic dysfunction-associated steatohepatitis (MASH), a more advanced stage, carries a high risk of progression to liver fibrosis, cirrhosis, liver failure, and hepatocellular carcinoma. Until recently, lifestyle intervention remained the mainstay of MASH management, with no pharmacological treatments specifically approved. However, advances in understanding its pathophysiological mechanisms have fueled numerous clinical trials, culminating in the Food and Drug Administration's (FDA) approval of resmetirom as the first treatment for MASH in 2024. Additionally, many investigational drugs are nearing FDA approval or progressing through late-stage clinical trials. This review examines the current therapeutic landscape, highlights strategies for identifying patients suitable for liver-directed therapies in real-world settings, and discusses the challenges that remain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.